Pictet Asset Management Holding SA Sells 340,838 Shares of Vera Therapeutics, Inc. $VERA

Pictet Asset Management Holding SA reduced its stake in Vera Therapeutics, Inc. (NASDAQ:VERA) by 24.5% in the 1st quarter, Holdings Channel reports. The firm owned 1,051,583 shares of the company’s stock after selling 340,838 shares during the period. Pictet Asset Management Holding SA’s holdings in Vera Therapeutics were worth $42,305,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD raised its position in shares of Vera Therapeutics by 49.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock valued at $276,595,000 after purchasing an additional 1,795,537 shares during the period. Deerfield Management Company L.P. lifted its stake in shares of Vera Therapeutics by 8.8% in the third quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock worth $105,812,000 after buying an additional 293,040 shares during the last quarter. Vanguard Group Inc. grew its stake in Vera Therapeutics by 11.9% in the 4th quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock valued at $180,805,000 after buying an additional 379,748 shares during the last quarter. Vestal Point Capital LP raised its holdings in Vera Therapeutics by 24.0% in the 2nd quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock worth $73,036,000 after acquiring an additional 600,000 shares during the period. Finally, Eversept Partners LP raised its holdings in Vera Therapeutics by 9.4% in the 4th quarter. Eversept Partners LP now owns 3,072,304 shares of the company’s stock worth $155,581,000 after acquiring an additional 264,468 shares during the period. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Price Performance

NASDAQ:VERA opened at $42.91 on Wednesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64. Vera Therapeutics, Inc. has a one year low of $19.07 and a one year high of $56.05. The company has a fifty day moving average price of $36.09 and a 200 day moving average price of $41.43. The stock has a market cap of $3.08 billion, a P/E ratio of -7.75 and a beta of 0.93.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period in the prior year, the business posted ($0.81) EPS. Analysts anticipate that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current year.

Insider Buying and Selling at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 18,500 shares of the stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $37.93, for a total value of $701,705.00. Following the completion of the sale, the chief executive officer owned 198,244 shares in the company, valued at approximately $7,519,394.92. This trade represents a 8.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 59,951 shares of company stock valued at $2,392,387 in the last three months. 15.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on VERA shares. William Blair restated an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Jefferies Financial Group reissued a “buy” rating and set a $60.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $90.00 target price on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $78.00.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.